{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:33:27Z","timestamp":1790732007551,"version":"4.1.0"},"reference-count":149,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T00:00:00Z","timestamp":1518566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bloodreviews.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.blre.2018.02.001","type":"journal-article","created":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T12:34:45Z","timestamp":1518438885000},"page":"300-311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":134,"title":["A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-6864","authenticated-orcid":false,"given":"Maria Domenica","family":"Cappellini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vip","family":"Viprakasit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali T.","family":"Taher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2018.02.001_bb0005","series-title":"Guidelines for the management of transfusion dependent thalassaemia (TDT)","author":"Cappellini","year":"2014"},{"key":"10.1016\/j.blre.2018.02.001_bb0010","series-title":"Guidelines for the management of non transfusion dependent thalassaemia (NTDT)","author":"Taher","year":"2013"},{"key":"10.1016\/j.blre.2018.02.001_bb0015","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1749-6632.2010.05548.x","article-title":"Redefining thalassemia as a hypercoagulable state","volume":"1202","author":"Cappellini","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.blre.2018.02.001_bb0020","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1600-0609.2011.01623.x","article-title":"Health-related quality of life in adults with transfusion-independent thalassaemia intermedia compared to regularly transfused thalassaemia major: new insights","volume":"87","author":"Musallam","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2018.02.001_bb0025","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2471\/BLT.06.036673","article-title":"Global epidemiology of haemoglobin disorders and derived service indicators","volume":"86","author":"Modell","year":"2008","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.blre.2018.02.001_bb0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1750-1172-5-11","article-title":"Beta-thalassemia","volume":"5","author":"Galanello","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.blre.2018.02.001_bb0035","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/archdischild-2014-308112","article-title":"Thalassaemia in children: from quality of care to quality of life","volume":"100","author":"Amid","year":"2015","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.blre.2018.02.001_bb0040","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1182\/blood-2010-01-251348","article-title":"The inherited diseases of hemoglobin are an emerging global health burden","volume":"115","author":"Weatherall","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.02.001_bb0045","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1365-2141.2011.08742.x","article-title":"The challenge of haemoglobinopathies in resource-poor countries","volume":"154","author":"Weatherall","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.02.001_bb0050","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a013482","article-title":"Beta-thalassemia intermedia: a clinical perspective","volume":"2","author":"Musallam","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.blre.2018.02.001_bb0055","first-page":"704","article-title":"Inherited haemoglobin disorders: an increasing global health problem","volume":"79","author":"Weatherall","year":"2001","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.blre.2018.02.001_bb0060","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s12185-009-0432-0","article-title":"Iron chelation therapy in the management of thalassemia: the Asian perspectives","volume":"90","author":"Viprakasit","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2018.02.001_bb0065","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-2141.2008.07085.x","article-title":"Genetic variation and susceptibility to infection: the red cell and malaria","volume":"141","author":"Weatherall","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.02.001_bb0070","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1750-1172-9-97","article-title":"Haemoglobinopathies in Europe: health & migration policy perspectives","volume":"9","author":"Aguilar Martinez","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.blre.2018.02.001_bb0075","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(11)60283-3","article-title":"Thalassaemia","volume":"379","author":"Higgs","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2018.02.001_bb0080","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1309\/AJCP20UTTCAYKUDX","article-title":"Efficacy of advanced discriminating algorithms for screening on iron-deficiency anemia and beta-thalassemia trait: a multicenter evaluation","volume":"138","author":"Schoorl","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.blre.2018.02.001_bb0085","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/ijlh.12527","article-title":"Laboratory diagnosis of thalassemia","volume":"38 Suppl 1","author":"Brancaleoni","year":"2016","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.blre.2018.02.001_bb0090","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1365-2141.2010.08486.x","article-title":"Optimal management of beta thalassaemia intermedia","volume":"152","author":"Taher","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.02.001_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/vox.12201","article-title":"When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia","volume":"108","author":"Taher","year":"2015","journal-title":"Vox Sang"},{"key":"10.1016\/j.blre.2018.02.001_bb0100","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/anae.12591","article-title":"A narrative review of peri-operative management of patients with thalassaemia","volume":"69","author":"Staikou","year":"2014","journal-title":"Anaesthesia"},{"key":"10.1016\/j.blre.2018.02.001_bb0105","author":"HbVar"},{"key":"10.1016\/j.blre.2018.02.001_bb0110","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3324\/haematol.2014.114827","article-title":"Beta-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies","volume":"100","author":"Rivella","year":"2015","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.blre.2018.02.001_bb0115","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1182\/blood-2003-11-3957","article-title":"Evaluation of alpha hemoglobin stabilizing protein (AHSP) as a genetic modifier in patients with beta thalassemia","volume":"103","author":"Viprakasit","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.02.001_bb0120","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a011726","article-title":"Pathophysiology and clinical manifestations of the beta-thalassemias","volume":"2","author":"Nienhuis","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.blre.2018.02.001_bb0125","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2141.2008.07084.x","article-title":"Genetic modifiers of the beta-haemoglobinopathies","volume":"141","author":"Thein","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.02.001_bb0130","doi-asserted-by":"crossref","first-page":"18716","DOI":"10.1073\/pnas.0910142106","article-title":"Interaction of malaria with a common form of severe thalassemia in an Asian population","volume":"106","author":"O'Donnell","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2018.02.001_bb0135","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0268-960X(12)70005-X","article-title":"The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia","volume":"26","author":"Rivella","year":"2012","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2018.02.001_bb0140","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3324\/haematol.2012.066845","article-title":"Non-transfusion-dependent thalassemias","volume":"98","author":"Musallam","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2018.02.001_bb0145","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1182\/blood-2006-09-048868","article-title":"Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin","volume":"109","author":"Gardenghi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.02.001_bb0150","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1172\/JCI0215686","article-title":"The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation","volume":"110","author":"Nicolas","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2018.02.001_bb0155","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.bcmd.2015.05.011","article-title":"Hemoglobin level and morbidity in non-transfusion-dependent thalassemia","volume":"55","author":"Taher","year":"2015","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.blre.2018.02.001_bb0160","first-page":"1","article-title":"Factors affecting health-related quality of life in Thai children with thalassemia","volume":"10","author":"Thavorncharoensap","year":"2010","journal-title":"BMC Blood Disord"},{"key":"10.1016\/j.blre.2018.02.001_bb0165","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/MPH.0000000000000565","article-title":"Impact of burden of thalassemia major on health-related quality of life in Omani children","volume":"38","author":"Mevada","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.blre.2018.02.001_bb0170","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.adolescence.2003.11.011","article-title":"Brief report: depressive symptoms and quality of life in adolescents with b-thalassaemia","volume":"27","author":"Mikelli","year":"2004","journal-title":"J Adolesc"},{"key":"10.1016\/j.blre.2018.02.001_bb0175","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1196\/annals.1345.035","article-title":"Quality of life in thalassemia","volume":"1054","author":"Telfer","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.blre.2018.02.001_bb0180","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000057633","article-title":"Impact of thalassemia major on patients and their families","volume":"107","author":"Caro","year":"2002","journal-title":"Acta Haematol"},{"key":"10.1016\/j.blre.2018.02.001_bb0185","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1185\/03007990802160834","article-title":"Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study","volume":"24","author":"Scalone","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.blre.2018.02.001_bb0190","doi-asserted-by":"crossref","DOI":"10.47102\/annals-acadmedsg.V45N11p520","article-title":"Factors affecting quality of life in adult patients with thalassaemia major and intermedia","volume":"45","author":"Gan","year":"2016","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.blre.2018.02.001_bb0195","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1186\/s40064-016-3568-4","article-title":"Thalassemia major: how do we improve quality of life?","volume":"5","author":"Dhirar","year":"2016","journal-title":"Springerplus"},{"key":"10.1016\/j.blre.2018.02.001_bb0200","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/JBM.S27400","article-title":"Treating thalassemia major-related iron overload: the role of deferiprone","volume":"3","author":"Berdoukas","year":"2012","journal-title":"J Blood Med"},{"key":"10.1016\/j.blre.2018.02.001_bb0205","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2009.0034","article-title":"Iron chelation therapy in thalassemia syndromes","volume":"1","author":"Cianciulli","year":"2009","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.blre.2018.02.001_bb0210","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.pcl.2008.02.002","article-title":"Update on thalassemia: clinical care and complications","volume":"55","author":"Cunningham","year":"2008","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.blre.2018.02.001_bb0215","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/bjh.12177","article-title":"Pain in thalassaemia: the effects of age on pain frequency and severity","volume":"160","author":"Haines","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.02.001_bb0220","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/sj.bmt.1705287","article-title":"Financial burden of national health insurance for treating patients with transfusion-dependent thalassemia in Taiwan","volume":"37","author":"Ho","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2018.02.001_bb0225","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/trf.13513","article-title":"Healthcare costs and outcomes of managing beta-thalassemia major over 50 years in the United Kingdom","volume":"56","author":"Weidlich","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2018.02.001_bb0230","first-page":"111","article-title":"Economic burden of thalassemia major in Iran, 2015","volume":"16","author":"Esmaeilzadeh","year":"2016","journal-title":"J Res Health Sci"},{"key":"10.1016\/j.blre.2018.02.001_bb0235","article-title":"Hemoglobinopathy: molecular epidemiological characteristics and health effects on Hakka people in the Meizhou region, southern China","volume":"8","author":"Lin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2018.02.001_bb0240","first-page":"786","article-title":"Thalassaemia in Sri Lanka: implications for the future health burden of Asian populations","volume":"355","author":"de Silva","year":"2000","journal-title":"Sri Lanka Thalassaemia Study Group Lancet"},{"key":"10.1016\/j.blre.2018.02.001_bb0245","first-page":"687","article-title":"Evaluation and cost analysis of national health policy of thalassaemia screening in West-Azerbaijan province of Iran","volume":"3","author":"Ahmadnezhad","year":"2012","journal-title":"Int J Prev Med"},{"key":"10.1016\/j.blre.2018.02.001_bb0250","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1056\/NEJMra050436","article-title":"Beta-thalassemia","volume":"353","author":"Rund","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.02.001_bb0255","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1537-2995.1997.37297203514.x","article-title":"A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis","volume":"37","author":"Cazzola","year":"1997","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2018.02.001_bb0260","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1182\/blood-2009-09-243154","article-title":"Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study","volume":"115","author":"Taher","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.02.001_bb0265","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1537-2995.2007.01192.x","article-title":"Thalassemia intermedia today: should patients regularly receive transfusions?","volume":"47","author":"Aessopos","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2018.02.001_bb0270","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1365-3148.2007.00797.x","article-title":"Factors that motivate and hinder blood donation in Greece","volume":"17","author":"Marantidou","year":"2007","journal-title":"Transfus Med"},{"key":"10.1016\/j.blre.2018.02.001_bb0275","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.clinthera.2014.05.003","article-title":"The cost of blood collection in Greece: an economic analysis","volume":"36","author":"Fragoulakis","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.blre.2018.02.001_bb0280","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1423-0410.1987.tb02999.x","article-title":"Alloimmunization to red cell antigens in thalassemia: comparative study of usual versus better-match transfusion programmes","volume":"52","author":"Michail-Merianou","year":"1987","journal-title":"Vox Sang"},{"key":"10.1016\/j.blre.2018.02.001_bb0285","first-page":"50","article-title":"Red cell alloantibodies in patients with thalassemia","volume":"58","author":"Spanos","year":"1990","journal-title":"Vox Sang"},{"key":"10.1016\/j.blre.2018.02.001_bb0290","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1111\/trf.13695","article-title":"Study of red blood cell alloimmunization risk factors in multiply transfused thalassemia patients: role in improving thalassemia transfusion practice in Fayoum, Egypt","volume":"56","author":"Abdelrazik","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2018.02.001_bb0295","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2141.2011.08576.x","article-title":"Red cell alloimmunization in a diverse population of transfused patients with thalassaemia","volume":"153","author":"Thompson","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.02.001_bb0300","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/JBM.S61540","article-title":"Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives","volume":"7","author":"Bayanzay","year":"2016","journal-title":"J Blood Med"},{"key":"10.1016\/j.blre.2018.02.001_bb0305","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ajh.23876","article-title":"Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine","volume":"90","author":"Pennell","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2018.02.001_bb0310","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3324\/haematol.2011.049957","article-title":"Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with beta-thalassemia major","volume":"97","author":"Pennell","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2018.02.001_bb0315","first-page":"1187","article-title":"Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine","volume":"89","author":"Borgna-Pignatti","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2018.02.001_bb0320","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJM199409013310902","article-title":"Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major","volume":"331","author":"Brittenham","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.02.001_bb0325","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1056\/NEJM199009133231104","article-title":"Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major","volume":"323","author":"Bronspiegel-Weintrob","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.02.001_bb0330","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2147\/DDDT.S79458","article-title":"Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes","volume":"10","author":"Kontoghiorghe","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.blre.2018.02.001_bb0335","author":"Noridem Enterprises Ltd"},{"key":"10.1016\/j.blre.2018.02.001_bb0340","author":"Focus Pharmaceuticals Ltd"},{"key":"10.1016\/j.blre.2018.02.001_bb0345","author":"Novartis Pharmaceuticals UK Ltd"},{"key":"10.1016\/j.blre.2018.02.001_bb0350","author":"Novartis Pharmaceuticals Corporation"},{"key":"10.1016\/j.blre.2018.02.001_bb0355","author":"Novartis Pharma Stein AG"},{"key":"10.1016\/j.blre.2018.02.001_bb0360","author":"ApoPharma Inc"},{"key":"10.1016\/j.blre.2018.02.001_bb0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta13010","article-title":"Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation","volume":"13","author":"McLeod","year":"2009","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.blre.2018.02.001_bb0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5662\/wjm.v6.i1.1","article-title":"New developments and controversies in iron metabolism and iron chelation therapy","volume":"6","author":"Kontoghiorghe","year":"2016","journal-title":"World J Methodol"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2018.02.001_bb0375","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S0268-960X(08)70004-3","article-title":"Cardiac iron across different transfusion-dependent diseases","volume":"22","author":"Wood","year":"2008","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2018.02.001_bb0380","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0037-1963(01)90061-7","article-title":"Deferoxamine pharmacokinetics","volume":"38","author":"Porter","year":"2001","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2018.02.001_bb0385","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1472-6963-13-45","article-title":"Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program","volume":"13","author":"Sruamsiri","year":"2013","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.blre.2018.02.001_bb0390","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.bcmd.2014.04.006","article-title":"Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients","volume":"53","author":"Cassinerio","year":"2014","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.blre.2018.02.001_bb0395","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/asheducation-2010.1.451","article-title":"Update on iron chelators in thalassemia","volume":"2010","author":"Neufeld","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2018.02.001_bb0400","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/ejh.12487","article-title":"Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study","volume":"95","author":"Aydinok","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2018.02.001_bb0405","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1111\/j.1537-2995.2007.01416.x","article-title":"Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review","volume":"47","author":"Delea","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2018.02.001_bb0410","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s40261-012-0008-2","article-title":"Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective","volume":"32","author":"Karnon","year":"2012","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.blre.2018.02.001_bb0415","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00019053-200725040-00005","article-title":"Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective","volume":"25","author":"Delea","year":"2007","journal-title":"Pharmacoeconomics"},{"issue":"12 Suppl 3","key":"10.1016\/j.blre.2018.02.001_bb0420","first-page":"S7881","article-title":"A time-cost augmented economic evaluation of oral deferasirox versus infusional deferoxamine [corrected] for patients with iron overload in South Korea","author":"Kim","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.blre.2018.02.001_bb0425","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2012-10-408021","article-title":"Clinical experience with fetal hemoglobin induction therapy in patients with beta-thalassemia","volume":"121","author":"Musallam","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.02.001_bb0430","article-title":"Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias","volume":"10","author":"Foong","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.blre.2018.02.001_bb0435","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.hemonc.2017.02.002","article-title":"Hydroxyurea for nontransfusion-dependent beta-thalassemia: a systematic review and meta-analysis","volume":"10","author":"Algiraigri","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.blre.2018.02.001_bb0440","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ejim.2011.05.013","article-title":"Risk factors for pulmonary hypertension in patients with beta thalassemia intermedia","volume":"22","author":"Karimi","year":"2011","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.blre.2018.02.001_bb0445","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/ajh.22102","article-title":"Changing patterns of splenectomy in transfusion-dependent thalassemia patients","volume":"86","author":"Piga","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2018.02.001_bb0450","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2013.099747","article-title":"Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel","volume":"99","author":"Angelucci","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2018.02.001_bb0455","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/bmt.2015.293","article-title":"Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000\u20132010","volume":"51","author":"Baronciani","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2018.02.001_bb0460","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.bbmt.2010.09.011","article-title":"Prospective assessment of health-related quality of life in pediatric patients with beta-thalassemia following hematopoietic stem cell transplantation","volume":"17","author":"Caocci","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2018.02.001_bb0465","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3109\/08880018.2012.693577","article-title":"Quality of life assessment in hematopoietic stem cell transplantation performed on thalassemia major patients","volume":"29","author":"Uygun","year":"2012","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.blre.2018.02.001_bb0470","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/bmt.2008.165","article-title":"Quality of life in patients with transfusion-dependent thalassemia after hematopoietic SCT","volume":"42","author":"Cheuk","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2018.02.001_bb0475","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/MOH.0000000000000286","article-title":"Matched sibling donor hematopoietic stem cell transplantation for thalassemia","volume":"23","author":"Issaragrisil","year":"2016","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.blre.2018.02.001_bb0480","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/MOH.0000000000000280","article-title":"Transplantation for thalassemia major: alternative donors","volume":"23","author":"Locatelli","year":"2016","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.blre.2018.02.001_bb0485","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.bbmt.2017.02.002","article-title":"Hematopoietic stem cell transplantation using preimplantation genetic diagnosis and human leukocyte antigen typing for human leukocyte antigen\u2013matched sibling donor: a Turkish multicenter study","volume":"23","author":"Kurekci","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2018.02.001_bb0490","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/1472-6963-10-209","article-title":"A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand","volume":"10","author":"Leelahavarong","year":"2010","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.blre.2018.02.001_bb0495","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.bbmt.2012.10.025","article-title":"Hematopoietic cell transplantation for thalassemia: a global perspective BMT tandem meeting 2013","volume":"19","author":"Mehta","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2018.02.001_bb0500","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1634\/theoncologist.2014-0218","article-title":"Cost structure and clinical outcome of a stem cell transplantation program in a developing country: the experience in northeast Mexico","volume":"20","author":"Jaime-Perez","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.blre.2018.02.001_bb0505","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.bbmt.2012.04.002","article-title":"Costs and cost-effectiveness of allogeneic stem cell transplantation in children are predictable","volume":"18","author":"Matthes-Martin","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2018.02.001_bb0510","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/2040620716653729","article-title":"The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challenges","volume":"7","author":"Goodman","year":"2016","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2018.02.001_bb0515","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032345","article-title":"Therapeutic hemoglobin levels after gene transfer in beta-thalassemia mice and in hematopoietic cells of beta-thalassemia and sickle cells disease patients","volume":"7","author":"Breda","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2018.02.001_bb0520","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/35017565","article-title":"Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin","volume":"406","author":"May","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.blre.2018.02.001_bb0525","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1182\/blood.V99.6.1902","article-title":"Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene","volume":"99","author":"May","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.02.001_bb0530","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1182\/blood-2002-10-3305","article-title":"A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer","volume":"101","author":"Rivella","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.02.001_bb0535","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia","volume":"467","author":"Cavazzana-Calvo","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.blre.2018.02.001_bb0540","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood.V128.22.1175.1175","article-title":"Lentiglobin gene therapy for transfusion-dependent \u03b2-thalassemia: update from the Northstar HGB-204 Phase 1\/2 clinical study","volume":"128","author":"Thompson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.02.001_bb0545","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1126\/science.1242088","article-title":"An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level","volume":"342","author":"Bauer","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.blre.2018.02.001_bb0550","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/507894","article-title":"Induction of fetal hemoglobin in vivo mediated by a synthetic gamma-globin zinc finger activator","volume":"2012","author":"Costa","year":"2012","journal-title":"Anemia"},{"key":"10.1016\/j.blre.2018.02.001_bb0555","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/mt.2015.113","article-title":"miRNA-embedded shRNAs for lineage-specific BCL11A knockdown and hemoglobin F induction","volume":"23","author":"Guda","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2018.02.001_bb0560","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1182\/blood.V128.22.3623.3623","article-title":"Crispr\/Cas9\u2013 mediated genome editing of human CD34+ cells upregulate fetal hemoglobin to clinically relevant levels in single cell-derived erythroid colonies","volume":"128","author":"Mishra","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.02.001_bb0565","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1749-6632.2009.04569.x","article-title":"Complex and context dependent regulation of hematopoiesis by TGF-beta superfamily signaling","volume":"1176","author":"Soderberg","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.blre.2018.02.001_bb0570","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/938640","article-title":"Beta-thalassemia: hiJAKing ineffective erythropoiesis and iron overload","volume":"2010","author":"Melchiori","year":"2010","journal-title":"Adv Hematol"},{"key":"10.1016\/j.blre.2018.02.001_bb0575","author":"Novartis Europharm Limited"},{"key":"10.1016\/j.blre.2018.02.001_bb0580","author":"Incyte Corp"},{"key":"10.1016\/j.blre.2018.02.001_bb0585","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis","volume":"86","author":"Tefferi","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2018.02.001_bb0590","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40273-013-0083-0","article-title":"Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal","volume":"31","author":"Wade","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.blre.2018.02.001_bb0595","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40273-016-0447-3","article-title":"A review of ruxolitinib for the treatment of myelofibrosis: a critique of the evidence","volume":"35","author":"Wade","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.blre.2018.02.001_bb0600","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood-2007-12-126938","article-title":"Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia","volume":"112","author":"Libani","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.02.001_bb0605","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.3324\/haematol.2017.181511","article-title":"Short-term administration of JAK2 inhibitors reduces splenomegaly in mouse models of ss-thalassemia intermedia and major","volume":"103","author":"Casu","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2018.02.001_bb0610","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1182\/blood-2017-06-790121","article-title":"Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study","volume":"131","author":"Taher","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.02.001_bb0615","first-page":"303","article-title":"Novel erythropoiesis stimulating agents in thalassemia","volume":"9","author":"Porter","year":"2015","journal-title":"Hematol Educ"},{"key":"10.1016\/j.blre.2018.02.001_bb0620","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1359\/jbmr.081208","article-title":"Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women","volume":"24","author":"Ruckle","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.blre.2018.02.001_bb0625","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/jcph.160","article-title":"Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women","volume":"53","author":"Sherman","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.blre.2018.02.001_bb0630","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ajh.23732","article-title":"A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers","volume":"89","author":"Attie","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2018.02.001_bb0635","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1101\/gad.1021802","article-title":"Activin type IIA and IIB receptors mediate Gdf11 signaling in axial vertebral patterning","volume":"16","author":"Oh","year":"2002","journal-title":"Genes Dev"},{"key":"10.1016\/j.blre.2018.02.001_bb0640","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.3512","article-title":"Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis","volume":"20","author":"Suragani","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2018.02.001_bb0645","first-page":"17","article-title":"Interim results from a phase 2a, open-label, dose-finding study of sotatercept (ACE-011) in adult patients with beta-thalassemia (S137)","volume":"100","author":"Cappellini","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2018.02.001_bb0650","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/bjh.12838","article-title":"An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin","volume":"165","author":"Carrancio","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.02.001_bb0655","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nm.3468","article-title":"An activin receptor IIA ligand trap corrects ineffective erythropoiesis in beta-thalassemia","volume":"20","author":"Dussiot","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2018.02.001_bb0660","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.V126.23.751.751","article-title":"Rap-536 (murine ACE-536\/luspatercept) inhibits Smad2\/3 signaling and promotes erythroid differentiation by restoring GATA-1 function in murine b-thalassemia","volume":"126","author":"Martinez","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.02.001_bb0665","first-page":"18","article-title":"RAP-536 (murine analog of ACE-536\/luspatercept) inhibits smad2\/3 signaling and promotes erythroid differentiation by restoring GATA-1 function in a murine model of \u03b2-thalassemia (S136)","volume":"101","author":"Martinez","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2018.02.001_bb0670","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1182\/blood-2013-06-511238","article-title":"Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine beta-thalassemia","volume":"123","author":"Suragani","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.02.001_bb0675","first-page":"338","article-title":"Luspatercept decreases transfusion burden and liver iron concentration in regularly transfused adults with beta-thalassemia (S836)","volume":"101","author":"Piga","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2018.02.001_bb0680","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.V128.22.851.851","article-title":"Luspatercept increases hemoglobin, decreases transfusion burden and improves iron overload in adults with beta-thalassemia","volume":"128","author":"Piga","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.02.001_bb0685","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood.V128.22.2463.2463","article-title":"Pharmacokinetics and exposure-response of luspatercept in patients with beta-thalassemia: preliminary results from phase 2 studies","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.02.001_bb0690","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1172\/JCI41717","article-title":"Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice","volume":"120","author":"Gardenghi","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2018.02.001_bb0695","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1172\/JCI57693","article-title":"Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload","volume":"121","author":"Preza","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2018.02.001_bb0700","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2015-10-676742","article-title":"Minihepcidin peptides as disease modifiers in mice affected by beta-thalassemia and polycythemia vera","volume":"128","author":"Casu","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.02.001_bb0705","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1182\/blood-2012-01-401885","article-title":"Deletion of TMPRSS6 attenuates the phenotype in a mouse model of beta-thalassemia","volume":"119","author":"Nai","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.02.001_bb0710","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1172\/JCI66969","article-title":"Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice","volume":"123","author":"Guo","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2018.02.001_bb0715","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood-2012-09-453977","article-title":"An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe\u2212\/\u2212 mice and ameliorates anemia and iron overload in murine beta-thalassemia intermedia","volume":"121","author":"Schmidt","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.02.001_bb0720","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V128.22.1013.1013","article-title":"Developing a galnac-conjugated TMPRSS6 antisense therapy for the treatment of beta-thalassemia","volume":"128","author":"Aghajan","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.02.001_bb0725","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood-2016-09-742387","article-title":"Decreasing TfR1 expression reverses anemia and hepcidin suppression in beta-thalassemic mice","volume":"129","author":"Li","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.02.001_bb0730","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nm.2073","article-title":"Transferrin therapy ameliorates disease in beta-thalassemic mice","volume":"16","author":"Li","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2018.02.001_bb0735","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2015.127902","article-title":"Increased hepcidin in transferrin-treated thalassemic mice correlates with increased liver BMP2 expression and decreased hepatocyte ERK activation","volume":"101","author":"Chen","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2018.02.001_bb0740","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1053\/j.gastro.2011.03.007","article-title":"Hypoxia-inducible factor-2alpha mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice","volume":"140","author":"Taylor","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.blre.2018.02.001_bb0745","doi-asserted-by":"crossref","first-page":"E4922","DOI":"10.1073\/pnas.1314197110","article-title":"Intestinal HIF2alpha promotes tissue-iron accumulation in disorders of iron overload with anemia","volume":"110","author":"Anderson","year":"2013","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X17301303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X17301303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T02:04:27Z","timestamp":1660442667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X17301303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":149,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0268960X17301303"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2018.02.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2018.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}